Tyra Biosciences (NASDAQ:TYRA) Downgraded to “Sell” Rating by Wall Street Zen

Tyra Biosciences (NASDAQ:TYRA) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

TYRA has been the topic of a number of other reports. Piper Sandler raised their target price on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday. Wedbush increased their price target on Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Tyra Biosciences Stock Down 1.7%

Shares of TYRA opened at $30.37 on Friday. Tyra Biosciences has a 52-week low of $6.42 and a 52-week high of $31.56. The stock has a market cap of $1.62 billion, a PE ratio of -16.24 and a beta of 1.07. The firm’s fifty day moving average is $24.66 and its two-hundred day moving average is $16.77.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). As a group, research analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the director owned 3,823,425 shares of the company’s stock, valued at $95,585,625. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its holdings in shares of Tyra Biosciences by 28.2% in the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after buying an additional 89,024 shares during the period. Goldman Sachs Group Inc. grew its position in Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after acquiring an additional 13,896 shares in the last quarter. Woodline Partners LP acquired a new position in Tyra Biosciences in the 1st quarter valued at about $931,000. Jane Street Group LLC purchased a new stake in Tyra Biosciences during the first quarter worth about $324,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Tyra Biosciences during the second quarter worth about $177,000. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.